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Background
Most deaths in thalassemia major (TM) result from
cardiac complications due to iron overload. No data are
available in literature about possible different changes in
cardiac iron in TM patients treated with sequential deferi-
pron-deferoxamine (DFP-DFO) versus deferasirox (DFX).
Magnetic Resonance (MR) is the unique non invasive sui-
table technique to evaluated quantitatively this issue.
Aims
Our aim was to prospectively assess the efficacy of
the DFP-DFO vs DFX in a cohort of TM patients by
quantitative MR.
Methods
Among the first 739 TM patients enrolled in the MIOT
(Myocardial Iron Overload in Thalassemia) network,
253 patients performed a MR follow up study at 18 ±
3 months according to the protocol. We evaluated pro-
spectively the 25 patients treated with DFP-DFO versus
the 44 patients treated with DFX between the 2 MR
scans. Myocardial iron concentrations were measured by
T2* multislice multiecho technique.
Results
Excellent/good levels of compliance were similar in the 2
groups (DFP-DFO 96% vs DFX 100%; P=0.36). At baseline
the 2 groups were homogeneous for cardiac iron. Among
the patients with no significant myocardial iron overload
(MIO) at baseline (global heart T2* ≥ 20 ms), there were
no significant differences between groups to maintain the
patients without myocardial iron overload (DFP-DFO 95%
vs DFX 96%; P =1.0). Among the patients with MIO at
baseline (global heart T2* < 20 ms), only in the DFX
group there was a significant improvement in the global
heart T2* value (11 ± 5 ms at baseline versus 16 ± 8 at
18 ± 3 months, P=0.0001) and in the number of segment
with a normal T2* value (P=0.003). The improvement in
the global heart T2* was not significantly different in the
DFP-DFO versus the DFX group (mean difference global
heart T2* 2.2 ± 4.1 ms versus 4.6 ± 4.8 P=0.2). Conclu-
sions: Prospectively in the clinical setting over 15 months
we did not find significant differences on cardiac iron by
quantitative MRI in TM patients treated with sequential
DFP-DFO versus the TM patients treated with DFX.
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